Sage Mountain Advisors’s Pacira BioSciences PCRX Stock Holding History

Sage Mountain Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-37	Closed	-$2K	–	679
2021 Q4	$2K	Buy	+37	New	+$2.04K	﹤0.01%	685
2021 Q3	–	Sell	-8	Closed	–	–	588
2021 Q2	$0	Buy	+8	New	+$506	﹤0.01%	529

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Sage Mountain Advisors's PCRX Position: Q1 2022 in Review

Sage Mountain Advisors sold out of Pacira BioSciences (PCRX) in Q1 2022, closing a stake of 37 shares — an estimated $2K sold.

Sage Mountain Advisors first reported a position in PCRX in Q2 2021 and held it in 2 quarters. The position peaked at $2K in Q4 2021. 301 funds tracked by Wall St. Rank hold PCRX as of Q1 2022.

Sage Mountain Advisors reported no remaining Pacira BioSciences position as of Q1 2022 after selling out during the quarter.
Sage Mountain Advisors sold 37 Pacira BioSciences shares in Q1 2022, an estimated $2K.
Sage Mountain Advisors first reported a position in Pacira BioSciences in Q2 2021 and held it in 2 quarters.
Sage Mountain Advisors's Pacira BioSciences position peaked at $2K in Q4 2021.
301 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2022.

Based on Sage Mountain Advisors's 13F filing for Q1 2022, filed 10 May 2022.